Operating Lease, Liability, Noncurrent of Adaptimmune Therapeutics PLC from 31 Mar 2019 to 30 Jun 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
- Summary
-
Adaptimmune Therapeutics PLC quarterly Operating Lease, Liability, Noncurrent in USD history and change rate from 31 Mar 2019 to 30 Jun 2025.
- Adaptimmune Therapeutics PLC Operating Lease, Liability, Noncurrent for the quarter ending 30 Jun 2025 was $18,491,000, a 8.1% increase year-over-year.
- Source SEC data
- View on sec.gov
Operating Lease, Liability, Noncurrent, Quarterly (USD)
Operating Lease, Liability, Noncurrent, YoY Quarterly Change (%)
Adaptimmune Therapeutics PLC Quarterly Operating Lease, Liability, Noncurrent (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | $18,491,000 | +$1,390,000 | +8.1% | 30 Jun 2025 | 10-Q | 13 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $18,668,000 | +$226,000 | +1.2% | 31 Mar 2025 | 10-Q | 13 May 2025 | 2025 | Q1 |
| Q4 2024 | $19,263,000 | -$588,000 | -3% | 31 Dec 2024 | 10-Q | 13 Aug 2025 | 2025 | Q2 |
| Q3 2024 | $20,455,000 | -$65,000 | -0.32% | 30 Sep 2024 | 10-Q | 13 Nov 2024 | 2024 | Q3 |
| Q2 2024 | $17,101,000 | -$4,489,000 | -21% | 30 Jun 2024 | 10-Q | 12 Aug 2024 | 2024 | Q2 |
| Q1 2024 | $18,442,000 | -$1,549,000 | -7.7% | 31 Mar 2024 | 10-Q | 15 May 2024 | 2024 | Q1 |
| Q4 2023 | $19,851,000 | -$498,000 | -2.4% | 31 Dec 2023 | 10-K | 24 Mar 2025 | 2024 | FY |
| Q3 2023 | $20,520,000 | +$594,000 | +3% | 30 Sep 2023 | 10-Q | 08 Nov 2023 | 2023 | Q3 |
| Q2 2023 | $21,590,000 | -$45,000 | -0.21% | 30 Jun 2023 | 10-Q | 09 Aug 2023 | 2023 | Q2 |
| Q1 2023 | $19,991,000 | -$3,229,000 | -14% | 31 Mar 2023 | 10-Q | 12 May 2023 | 2023 | Q1 |
| Q4 2022 | $20,349,000 | -$2,799,000 | -12% | 31 Dec 2022 | 10-K | 06 Mar 2024 | 2023 | FY |
| Q3 2022 | $19,926,000 | -$3,778,000 | -16% | 30 Sep 2022 | 10-Q | 08 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $21,635,000 | +$1,912,000 | +9.7% | 30 Jun 2022 | 10-Q | 04 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $23,220,000 | +$3,323,000 | +17% | 31 Mar 2022 | 10-Q | 09 May 2022 | 2022 | Q1 |
| Q4 2021 | $23,148,000 | +$2,210,000 | +11% | 31 Dec 2021 | 10-K | 06 Mar 2023 | 2022 | FY |
| Q3 2021 | $23,704,000 | +$2,614,000 | +12% | 30 Sep 2021 | 10-Q | 04 Nov 2021 | 2021 | Q3 |
| Q2 2021 | $19,723,000 | -$1,091,000 | -5.2% | 30 Jun 2021 | 10-Q | 09 Aug 2021 | 2021 | Q2 |
| Q1 2021 | $19,897,000 | -$1,932,000 | -8.9% | 31 Mar 2021 | 10-Q | 06 May 2021 | 2021 | Q1 |
| Q4 2020 | $20,938,000 | -$2,028,000 | -8.8% | 31 Dec 2020 | 10-K | 14 Mar 2022 | 2021 | FY |
| Q3 2020 | $21,090,000 | -$1,509,000 | -6.7% | 30 Sep 2020 | 10-Q | 05 Nov 2020 | 2020 | Q3 |
| Q2 2020 | $20,814,000 | -$2,852,000 | -12% | 30 Jun 2020 | 10-Q | 06 Aug 2020 | 2020 | Q2 |
| Q1 2020 | $21,829,000 | -$4,950,000 | -18% | 31 Mar 2020 | 10-Q | 14 May 2020 | 2020 | Q1 |
| Q4 2019 | $22,966,000 | 31 Dec 2019 | 10-K | 25 Feb 2021 | 2020 | FY | ||
| Q3 2019 | $22,599,000 | 30 Sep 2019 | 10-Q | 06 Nov 2019 | 2019 | Q3 | ||
| Q2 2019 | $23,666,000 | 30 Jun 2019 | 10-Q | 01 Aug 2019 | 2019 | Q2 | ||
| Q1 2019 | $26,779,000 | 31 Mar 2019 | 10-Q | 06 May 2019 | 2019 | Q1 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.